Royalty Pharma Plc (NASDAQ: RPRX)
Royalty Pharma Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Royalty Pharma Plc Company Info
Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
News & Analysis
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
Analysts are quite bullish about these beaten-down stocks.
2 Dividend Stocks Wall Street Thinks Can Rise by 50%
These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit.
Here's What Caused Royalty Pharma's Mixed Results in Q4
The company's royalties revenue soared, but its earnings sank.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.